Description

Amgen: The Long-Acting Obesity Breakthrough Investors Are Watching Closely!

Amgen reported a solid first quarter in 2026 marked by 4% growth in product sales and a strong contribution from six key growth drivers, which together accounted for nearly 70% of total product sales and grew 24% year-over-year. This performance helped mitigate the financial impact of patent expirations and competitive pressures, particularly on legacy products such as Prolia and XGEVA, which experienced a combined 32% sales decline. The company’s diversified portfolio spans general medicine, inflammation, rare disease, oncology, and biosimilars, reflecting a broad therapeutic focus. Repatha demonstrated significant momentum with a 34% sales increase driven by updated clinical guidelines advocating earlier and more intensive LDL-C lowering, which, supported by robust clinical data including the VESALIUS-CV study, is encouraging expanded use in both primary and secondary cardiovascular prevention. EVENITY and TEZSPIRE also showed strong growth, with market share gains and increased patient adoption in their respective categories.